DMRA peer analysis
Damora Therapeutics (DMRA) against its competitors: price, today's move, 1-year return and market value side by side.
DMRA and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| COAG Hemab | $42.66 | -12.96% | – | – |
| GERN Geron | $0.99 | 0.07% | -8.29% | $638.12M |
| GMAB Genmab | $55.81 | 4.06% | 93.52% | $34.83B |
| INCY Incyte | $121.91 | 1.88% | 15.88% | $24.85B |
| IRON Disc Medicine | $81.29 | 3.02% | -6.56% | $3.70B |
| KROS Keros Therapeutics | $9.13 | -2.46% | -43.54% | $179.17M |
| QURE uniQure | $22.81 | 5.12% | -17.08% | $1.60B |
| RIGL Rigel Pharmaceuticals | $41.93 | 5.75% | 16.09% | $789.54M |
| DMRA Damora Therapeutics | $24.09 | 1.65% | – | $1.49B |
- DMRA's peers: COAG (Hemab), GERN (Geron), GMAB (Genmab), INCY (Incyte), IRON (Disc Medicine), KROS (Keros Therapeutics), QURE (uniQure), RIGL (Rigel Pharmaceuticals).
Updated 2026-11-10 04:45 UTC